Ahead Therapeutics is a biotech start-up dedicated to developing advanced treatments for autoimmune disorders using its proprietary technology, MiMi-ToP (Mimicking Tolerogenic Particles).
Ahead Therapeutics has developed an innovative solution utilizing phosphatidylserine (PS)-liposomes to encapsulate disease-causing autoantigens. Through a biomimetic process, these PS-liposomes trigger antigen-specific immune tolerance, effectively halting the autoimmune attack.
By simply modifying the encapsulated autoantigen, Ahead’s technology can be applied to treat a variety of autoimmune conditions, including Type 1 Diabetes, Multiple Sclerosis, and Celiac Disease, among others.
While the technology holds promise for preventive applications, it is primarily envisioned as a reverse therapeutic vaccine, offering the potential for a permanent cure.
Ahead Therapeutics’ MiMi-ToP platform has been successfully validated in animal models, with preclinical non-regulatory assays for several indications currently underway. The next phase involves regulatory preclinical studies, as well as expanding the pipeline to include new proof-of-concept treatments based on Ahead’s technology for additional indications.
To support its R&D efforts, Ahead Therapeutics operates a clean room facility in l’Arboç (Tarragona), where it produces the necessary PS-liposome batches in-house. This capability grants the company flexibility and independence in designing and conducting both in vivo and in vitro studies.
Autoimmune diseases impact 5-10% of the global population, often requiring lifelong palliative treatments that lower quality of life and impose significant societal costs.
Caring about patients with autoimmune diseases is Ahead’s main mission. Our efforts are dedicated to developing a therapy that can replace current chronic palliative treatments with a definitive healing. Leveraging our advanced nanotechnology, we help the immune system recognize and correct its errors, halting attacks on healthy tissues. This process generates tolerance to specific auto-antigens while preserving overall immune function.
Our approach, based on Nano-technology, has allowed us to develop a powerful and highly specific pharmacological platform designed to treat and cure Autoimmune diseases.
Myasthenia Gravis, Type 1 Diabetes, Multiple Sclerosis, Celiac Disease, Rheumatoid Arthritis, Neuromyelitis Optica, Immune Thrombotic Thrombocytopenic Purpura, and more.
Our strategic alliances help accelerate innovation and expand patient impact. We are always open to exploring new opportunities that align with with our mission to restore immune balance and improve quality of live.
CEO
CTO – CMC Director
Ahead Therapeutics is a biotechnology company with a team of experienced professionals who are dedicated to developing groundbreaking therapies for autoimmune and inflammatory diseases. Led by CEO Marti Dalmases, the team includes experts in immunology, drug development, and business management. They are committed to bringing life-changing treatments to patients in need.
